Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
EDX Medical Group PLC on Thursday said that it has entered a strategic agreement with Guardant Health Inc to distribute its blood-based liquid biopsy tests in the UK and the Nordics.
EDX Medical is a Cambridge, England-based company that develops digital diagnostic products and services for the treatment of cancer, heart disease, and infectious diseases.
Guardant Health is a Palo Alto, California-based precision oncology company focused on helping to beat cancer through use of its proprietary tests, data sets and advanced analytics.
Under the agreement, EDX Medical will distribute the Guardant360 CDx test and the Guardant Reveal test to the private healthcare sector in the UK.
The former is for genomic testing in advanced cancer, while the latter is for residual disease and recurrence detection in early-stage cancer.
EDX Medical will also distribute Guardant360 CDx to public and private sectors in Sweden, Denmark, Norway, Finland and Iceland.
It will provide a local service, including optional home-based blood sample collection.
‘I’m delighted to be working with the scientific leaders at Guardant Health. This agreement provides our clients with access to world-class genomic testing products and the opportunity to join a group of thought leaders in personalised medicine,’ said Chief Executive Mike Hudson.
EDX Medical Group shares last traded at 2.00 pence each on Aquis on Wednesday.
Copyright 2023 Alliance News Ltd. All Rights Reserved.